S16 Ep28: Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

In this podcast, experts Naval Daver, MD; Courtney DiNardo, MD; and Eunice Wang, MD; discuss the rationale for treatment with menin inhibitors—and the data showing their efficacy and safety—in acute myeloid leukemia (AML).

In this episode, Gregory J. Tiesi, MD, FACS, FSSO, hosted a discussion about the growing role for transarterial microperfusion (TAMP) as a regional therapy strategy for patients with locally advanced pancreatic ductal adenocarcinoma (PDAC). Dr Tiesi is the medical director of Hepatobiliary Surgery at the Hackensack Meridian Jersey Shore University Medical Center in Neptune, New Jersey. He was joined by:  Anthony Scholer, MD, FACS, FSSO, a surgical oncologist specializing in hepatobiliary surgery at Hackensack Meridian Medical Group and Jersey Shore University Medical Center in Neptune, New Jersey  Eric Pletcher, MD, a surgeon specializing in Complex General Surgical Oncology at Hackensack Meridian JFK University Medical Center in Edison, New Jersey PDAC is a disease in which dense desmoplastic stroma and poor tumor vascularization often limit the effectiveness of standard systemic chemotherapy. Drs Tiesi, Scholer, and Pletcher explained that standard regimens, such as FOLFIRINOX or gemcitabine-based combinations, frequently fail to achieve adequate intratumoral drug concentrations because of these biologic barriers. TAMP aims to overcome this limitation by isolating a segment of an arterial vessel and pressure-mediated transvascular delivery, which would allow for higher local drug concentrations and reduce systemic exposure and toxicity. The experts noted that TAMP is currently being explored primarily in patients with locally advanced, unresectable pancreatic cancer without distant metastases, particularly those who have exhausted systemic treatment options but maintain localized disease. Early clinical studies, including the phase 1/2 RR1 trial (NCT02237157) and the observational RR2 dose-escalation study (NCT02591082), demonstrated that the procedure is technically feasible, repeatable, and associated with lower systemic toxicity compared with conventional chemotherapy. A pooled analysis of these studies suggested encouraging survival outcomes, particularly in patients who received prior chemoradiation, potentially because radiation modifies the tumor microenvironment and improves drug penetration. Lastly, Tiesi, Scholer and Pletcher reviewed the ongoing phase 3 TIGeR-PaC trial (NCT03257033), which is evaluating TAMP as a consolidation strategy after induction chemotherapy and radiation. Preliminary data suggest improved survival and substantially fewer serious adverse effects with TAMP vs continued systemic therapy alone. Although the experts cautioned that the approach remains investigational, they agreed that TAMP may provide meaningful local disease control and potentially expand treatment options and preserve quality of life for patients with this aggressive malignancy. 

In this podcast, experts Manish A. Shah, MD, FASCO; Syma Iqbal, MD; and Haeseong Park, MD, MPH; discuss novel combinations of targeted therapy, immunotherapy, and chemotherapy to treat resectable and unresectable gastroesophageal adenocarcinomas.

Welcome to OncLive On Air®! I’m your host today, Kyle Doherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today’s episode, we spoke with Sonali Smith, MD. Dr Smith holds the Elwood V. Jensen Professorship of Medicine and is the chief of the Section of Hematology/Oncology at UChicago Medicine. In our exclusive interview, Dr Smith discussed CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults. _____That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

In this podcast, experts Jacob Sands, MD; Marina Chiara Garassino, MD; and Eric Singhi, MD; use realistic cases to explore key decision points in applying HER2- and TROP2-targeted therapies across the non–small cell lung cancer (NSCLC) continuum, including patient selection, sequencing, and toxicity management.

In this podcast, experts Christine M. Lovly, MD, PhD, FASCO; Lyudmila Bazhenova, MD; Hossein Borghaei, DO, MS; and Xiuning Le, MD, PhD, discuss how to sequence systemic therapy based on the molecular profile of non–small cell lung cancer that has progressed on a first-line EGFR-directed tyrosine kinase inhibitor, including discussion on the use of bispecific antibodies in this setting.

In today’s episode, we sat down with Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI, as they shared their stories and perspectives as leading women in oncology in honor of International Women's Day, which is observed annually on March 8. Dr McCann is a breast medical oncologist in the University of California system. Dr Nunnery is a breast medical oncologist with Tennessee Oncology in Nashville.Forming the backdrop of our exclusive discussion were insights shared during the 2026 OncLive Women in Oncology event, which took place on March 5, 2026, to kick off the 43rd Annual Miami Breast Cancer Conference. In our exclusive interview, Drs McCann and Nunnery used the Women in Oncology discussion as the basis for relaying their own experiences, observations, and advice regarding setting boundaries, striving for work-life harmony, advocating for oneself, and more.

In today’s episode, we welcomed Saad Z. Usmani, MD, MBA, FACP, FASCO, to discuss the significance of the January 2026 FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).Usmani is chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York, and the recipient of the 2025 Giants of Cancer Care award for multiple myeloma.In the exclusive interview, Dr Usmani explained the clinical implications of the regulatory decision that expanded the indication for daratumumab plus VRd to the transplant-ineligible setting, detailed the pivotal data from the phase 3 CEPHEUS trial (NCT03652064) that supported the approval, and provided context for treatment strategies with this regimen in clinical practice.

In this podcast, experts Ashish M. Kamat, MD, MBBS, Katie S. Murray, DO, MS, and Thomas Powles, MD, MBBS, MRCP, discuss the classification of BCG responsiveness and intravesical and systemic therapies for non-muscle invasive bladder cancer.

In today’s episode, we spoke with Eric K. Singhi, MD. Dr Singhi is an assistant professor in the departments of general oncology and thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.Antibody-drug conjugates (ADCs) are rapidly emerging as one of the most exciting therapeutic advances in lung cancer. In this episode, Singhi explored how TROP2-directed ADCs are beginning to reshape treatment strategies across both non–small cell and small cell lung cancer.Singhi discussed where these agents currently fit within the treatment algorithm for EGFR-mutant non–small cell lung cancer, including the recent accelerated approval of datopotamab deruxtecan-dlnk (Datroway; Dato-DXd) and the evolving clinical data supporting its use after progression on targeted therapy and platinum-based chemotherapy. He also examined emerging evidence for other TROP2-targeting agents such as sacituzumab tirumotecan (sac-TMT) and what early trial results suggest about response rates and future treatment sequencing.Beyond efficacy, Singhi highlighted the practical considerations oncologists must navigate as ADCs enter routine practice, from managing chemotherapy-like toxicities to monitoring for unique adverse effects such as stomatitis, ocular effects, and interstitial lung disease.In our exclusive interview, Dr Singhi discussed where agents like dato-DXd and sac-TMT may fit in evolving treatment algorithms, the clinical data driving their momentum, and what oncologists should consider as these therapies move closer to routine practice in lung cancer.